These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 26646310)

  • 41. PPFIA1 is upregulated in liver metastasis of breast cancer and is a potential poor prognostic indicator of metastatic relapse.
    Yang J; Wu NN; Huang DJ; Luo YC; Huang JZ; He HY; Lu HL; Song WL
    Tumour Biol; 2017 Jul; 39(7):1010428317713492. PubMed ID: 28720060
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Estrogen receptor codon 594 and HER2 codon 655 polymorphisms and breast cancer risk.
    Akisik E; Dalay N
    Exp Mol Pathol; 2004 Jun; 76(3):260-3. PubMed ID: 15126109
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Different prognosis of young breast cancer patients in their 20s and 30s depending on subtype: a nationwide study from the Korean Breast Cancer Society.
    Ryu JM; Yu J; Kim SI; Kim KS; Moon HG; Choi JE; Jeong J; Do Byun K; Nam SJ; Lee JE; Lee SK; Kim SW
    Breast Cancer Res Treat; 2017 Dec; 166(3):833-842. PubMed ID: 28831642
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? No].
    Gampenrieder SP
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2097. PubMed ID: 24085365
    [No Abstract]   [Full Text] [Related]  

  • 46. ERBB2 and TOP2A in breast cancer: a comprehensive analysis of gene amplification, RNA levels, and protein expression and their influence on prognosis and prediction.
    Brase JC; Schmidt M; Fischbach T; Sültmann H; Bojar H; Koelbl H; Hellwig B; Rahnenführer J; Hengstler JG; Gehrmann MC
    Clin Cancer Res; 2010 Apr; 16(8):2391-401. PubMed ID: 20371687
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Abnormalities and clinical characteristics of growth factors and receptor systems in breast cancer].
    Kikuchi K; Ueda M; Ikeda T; Enomoto K; Kitajima M
    Gan To Kagaku Ryoho; 1994 Jun; 21 Suppl 2():168-71. PubMed ID: 7913599
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Predicting endocrine responsiveness: novel biomarkers on the horizon.
    Kerstann KF; Bouzyk M; Abramovitz M; Leyland-Jones B
    Oncology (Williston Park); 2009 Feb; 23(2):154, 156, 159. PubMed ID: 19323296
    [No Abstract]   [Full Text] [Related]  

  • 49. Dual HER2 Blockade Helps Prevent Breast Cancer Return.
    Cancer Discov; 2017 Aug; 7(8):790. PubMed ID: 28588061
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [A FISH analysis in one day. Experience in evaluating HER2 gene status by means of a new HER2 IQFISH pharmdx kit].
    Zavalishina LÉ; Petrov AV; Pavlenko IA; Gorelik MZ
    Arkh Patol; 2013; 75(1):52-3. PubMed ID: 23805475
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Prognostic value of ERBB family mRNA expression in breast carcinomas.
    Bièche I; Onody P; Tozlu S; Driouch K; Vidaud M; Lidereau R
    Int J Cancer; 2003 Sep; 106(5):758-65. PubMed ID: 12866037
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Prevalence of estrogen receptor variant messenger RNAs in human breast cancer.
    Leygue E; Huang A; Murphy LC; Watson PH
    Cancer Res; 1996 Oct; 56(19):4324-7. PubMed ID: 8813116
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Can circulating tumor cells predict resistance in metastatic breast cancer?
    Mathew A; Brufsky AM; Davidson NE
    Clin Cancer Res; 2015 Jun; 21(11):2421-3. PubMed ID: 25645864
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Are the new breast cancer subtypes (luminal A, B etc.) of practical impact? Yes].
    Stöger H
    Dtsch Med Wochenschr; 2013 Oct; 138(41):2096. PubMed ID: 24085364
    [No Abstract]   [Full Text] [Related]  

  • 55. Triple-negative breast cancer: unique biology and its management.
    Maegawa RO; Tang SC
    Cancer Invest; 2010 Oct; 28(8):878-83. PubMed ID: 20839950
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Relative Prognostic and Predictive Value of Gene Signature and Histologic Grade in Estrogen Receptor-Positive, HER2-Negative Breast Cancer.
    Iwamoto T; Kelly C; Mizoo T; Nogami T; Motoki T; Shien T; Taira N; Hayashi N; Niikura N; Fujiwara T; Doihara H; Matsuoka J
    Clin Breast Cancer; 2016 Apr; 16(2):95-100.e1. PubMed ID: 26631838
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Gene expression signatures for tailoring adjuvant chemotherapy of luminal breast cancer: stronger evidence, greater trust.
    Piccart MJ; Kalinsky K; Gray R; Barlow WE; Poncet C; Cardoso F; Winer E; Sparano J
    Ann Oncol; 2021 Sep; 32(9):1077-1082. PubMed ID: 34082017
    [No Abstract]   [Full Text] [Related]  

  • 58. [Association of HER2 genetic heterogeneity with clinicopathological characteristics in breast cancer].
    Yang YL; Fan Y; Lang RG; Gu F; Fu L
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2010 Oct; 27(5):540-5. PubMed ID: 20931533
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Personalizing extent of breast cancer surgery according to molecular subtypes.
    Morrow M
    Breast; 2013 Aug; 22 Suppl 2():S106-9. PubMed ID: 24074769
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Adjuvant chemotherapy is not for everyone.
    Henderson IC
    Breast Cancer Res Treat; 2010 Aug; 123(1):159-62. PubMed ID: 20549338
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.